Skip to content

A study on the effect of continuous erector spinae plane block guided by ultrasound on the rapid recovery of patients undergoing open hepatectomy and its cost analysis

A study on the effect of continuous erector spinae plane block guided by ultrasound on the rapid recovery of patients undergoing open hepatectomy and its cost analysis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900026583
Enrollment
Unknown
Registered
2019-10-15
Start date
2019-10-30
Completion date
Unknown
Last updated
2025-08-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

control group :Postoperative pain relief was achieved through the use of traditional intravenous pumps containing opioid drugs.
C-ESPB group:Postoperative use of ESPB combined with a non-opioid intravenous pump for analgesia

Sponsors

Fujian Provincial Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Hepatocellular carcinoma patients scheduled for elective open major hepatectomy under general anesthesia (resection of >= 3 liver segments), aged 18–80 years, with American Society of Anesthesiologists (ASA) physical status classification I–III, and Eastern Cooperative Oncology Group (ECOG) performance status score of 0–1.

Exclusion criteria

Exclusion criteria: 1. Patients who clearly asked for laparoscopic surgery; 2. Patients with a body mass index >= 30 kg/m2 or 2 times the normal upper limit); 8. Patients with severe spinal deformities; 9. Patients with distant tumor metastases; 10. Patients who had undergone hepatectomy (segment 50 mmHg; 16. Patients with poorly controlled acute or active infections (infection-induced fever > 38?); 17. Patients with poorly controlled hypertension or diabetes; 18. Patients with severe mental diseases or disorders; 19. Patients with suspicious systemic or regional nervous system diseases; 20. Patients with receiving systematic administration of corticosteroids; 21. Patients requiring concomitant surgical treatment for other diseases; 22. Patients with chronic pain or opioid use histories; 23. Women who were pregnant or breastfeeding; 24. Patients with other underlying serious diseases; 25. Patients who were unable or refused to comply with the treatment and monitoring required by the study; 26. Patients participating in other clinical trials; 27. Patients who refused to provide informed consent.

Design outcomes

Primary

MeasureTime frame
Area under the cumulative pain time curve at rest and movement 48 hours after surgery (AUCPACU-48h);

Secondary

MeasureTime frame
The incidence of postoperative nausea and vomiting;The time of the first defecation after the operation;Postoperative VAS score (PACU, 12 h, 24 h, 48 h, 72 h, 96 h);The frequency of postoperative remedial analgesic administration of NSAID and pethidine within the first 48 hours after the operation and after the first 48 hours after the operation;Postoperative hospital stay;The time of the first time out of bed after the operation;

Countries

China

Contacts

Public ContactWang Danfeng

Fujian Provincial Hospital

251487848@qq.com+86 139 0692 0551

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 10, 2026